Fig 6. Src-kinase activity is required for infection.

A549 cells were pre-treated with non-cytotoxic concentrations of the indicated Src-kinase inhibitors (PP2 [12.5 μM], SrcI-I [6.25 μM] or both) or mock-treated (DMSO carrier control) for 5 h. Cells were then inoculated with RSV-GFP (MOI = 1 PFU/cell) in media containing the indicated inhibitors. (A) Effect of Src-kinase inhibition on RSV infection. At 17 h p.i., GFP intensity was measured with an ELISA reader and expressed relative to mock-treated infected cells assigned the value of 1.0. (B) Titer of progeny RSV-GFP. At 24 h p.i. RSV titers were determined in replicate cultures by plaque titration on Vero cells. The statistical significance of the difference was determined by one-way analysis of variance with Tukey’s multiple-comparison post-test and p-values are shown for each comparison.